Vyriad

In The Know: Healthcare News For October 19, 2020

These small companies are making big COVID-19 contributions Odonata Health wins 2020 TFX Capital Showcase Health experts concerned ‘COVID fatigue’ causing a rise in cases Medtronic’s Pelvic Health Business Thrives Under the ‘New Medtronic’ Abbott Receives FDA Emergency Use Authorization for its COVID-19 IgM Antibody Blood Test United States Representative Angie Craig Visits Inspired Spine […]

IMPACT: Medical Alley and the COVID-19 Pandemic

Published October 15, 2020 Life, as we have known it, has changed. We celebrate the healthcare and public safety professionals, and the essential workers who continue to go to work every day to help others. We celebrate the acts of kindness and empathy; the countless recoveries and families reunited.  We continue to be in this […]

In The Know: Healthcare News for September 21, 2020

Blue Cross and Blue Shield of Minnesota Expands Access Statewide To Supportive Care Services From Livio Health Mayo scientists develop mathematical index to distinguish healthy microbiome from diseased Using Predictive Analytics to Target SDoH Interventions During COVID-19 FedEx SenseAware ID device expected to see use for COVID-19 vaccine shipments University of Minnesota R&D expenditures break […]

In The Know: Medical Alley News for July 27, 2020

Starkey President Brandon Sawalich Promoted to President and Chief Executive Officer Boston Scientific’s next-gen stroke prevention device gets FDA nod Blue Cross and Blue Shield of Minnesota Extends Coverage  of Expanded Telehealth Benefits Through 2020 Medtronic Foundation Commits $16M in Health and Education Partnerships to Address Racial Disparities and Advance Social Justice in Black Communities Humanetics […]

Medical Alley Startups Lead During Uncertain Half

Despite the tumultuous start to the year, early and growth stage companies in Medical Alley raised over $250 million, almost exactly the five-year average for the first half. Medical device companies in Medical Alley raised more than their counterparts anywhere else in the country. As the conversation around aging in place accelerates, Medical Alley is […]

Vyriad Inc. Announces Development of a New Antibody Test to Determine Protective Immunity From COVID-19

Vyriad test detects SARS-CoV-2 virus-neutralizing antibodies Developed as part of an ongoing collaboration with Regeneron ROCHESTER, Minn., May 12, 2020 (GLOBE NEWSWIRE) — Vyriad, Inc. announced today that it has completed the development of a serology test to measure protective immunity against SARS-CoV-2, the novel coronavirus that causes COVID-19. The Vyriad SARS-CoV-2 Neutralizing Antibody Test […]

Vyriad Inc. Names Experienced Life Sciences Investors Edwin Kania and Nathan Stacy to its Board of Directors

ROCHESTER, Minn., December 11, 2019 – Vyriad, Inc., a clinical-stage biotechnology company developing oncolytic virus therapies to treat a wide range of cancers, today announced the appointment of experienced life sciences investors Edwin M. Kania, Jr. and Nathan L. Stacy to the Company’s board of directors. Mr. Kania was named Chairman of the Board.  Mr. […]

In the Know: Healthcare News for November 27, 2019

Starkey Livio AI: The 100 Best Inventions of 2019 In Silicon Valley, startup cofounder battles VC over the future of health insurance Cancer-killing virus designer Vyriad raises $24.4 million 3M, Medtronic lead Minnesota companies on Management Top 250 list Mayo Clinic expands out of U.S. with Abu Dhabi hospital ExceleraRx, a network for expensive specialty […]

In the Know: Healthcare News for November 11, 2019

Stryker announces definitive agreement to acquire Wright Medical for $5.4 Billion Regeneron and Vyriad Announce Strategic Agreement for Discovery and Development of New Oncolytic Virus Treatments for Cancer Maple Grove-based Pursuit Vascular sold for $75 million to California firm Digi International spends $140 million to buy New Jersey IT company In $660 Million Deal, Takeda […]

Regeneron and Vyriad Announce Strategic Agreement for Discovery and Development of New Oncolytic Virus Treatments for Cancer

Phase 2 trial will evaluate combination of PD-1 inhibitor Libtayo® (cemiplimab-rwlc) and oncolytic virus Voyager-V1; preclinical research collaboration will explore new oncolytic virus treatments Vyriad to receive upfront payment and equity investment from Regeneron TARRYTOWN, N.Y., and ROCHESTER, Minn. (November 6, 2019) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Vyriad, Inc. today announced a research collaboration and option […]

Keep your finger on the pulse of Medical Alley from anywhere with the ALLEY NEWSLETTER